LingVo.club
Level
Emory study: 2023–24 COVID vaccine gives lasting antibodies — a close up of a bottle of medicine on a table

Emory study: 2023–24 COVID vaccine gives lasting antibodiesCEFR B1

2 Dec 2025

Adapted from Emory University, Futurity CC BY 4.0

Photo by Mufid Majnun, Unsplash

AI-assisted adaptation of the original article, simplified for language learners.

New research from Emory University evaluated immune responses after the 2023–24 COVID vaccine. The study, published in Science and Translational Medicine, followed 24 participants for six months and measured memory B cells, binding antibodies, and neutralizing antibodies. The 2023–24 vaccine was monovalent and designed to match the then-dominant Omicron XBB.1.5 variant; previous vaccines had been bivalent.

Laboratory tests showed the vaccine produced antibodies with a half-life of more than 500 days, so at least half remained detectable more than 16 months after vaccination. Participants also produced cross-reactive antibodies that recognized both the ancestral WA1 strain and XBB.1.5. The researchers said immune imprinting likely contributed to a 2.8-fold increase in these cross-reactive antibodies.

The paper notes that SARS-CoV-2 has caused more than 1.2 million deaths nationwide and has many mutations. It also lists groups at higher risk of severe disease, such as people with cancer, autoimmune disorders, stroke, obesity, and existing heart, kidney, lung, or liver conditions.

Difficult words

  • memory B cellsWhite blood cell that remembers past infections
  • binding antibodiesProtein that binds to a virus or germ
  • neutralizing antibodiesAntibody that can stop a virus infecting cells
  • monovalentDesigned to target one strain or variant
  • bivalentDesigned to target two different strains together
  • half-lifeTime for half of a substance to disappear
  • immune imprintingWhen first immune exposure shapes later responses

Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.

Discussion questions

  • Which of the risk groups named in the article would you put first for vaccine access in your community, and why?
  • If antibodies remain detectable for many months, how might that change people’s plans for booster shots?
  • How would you feel about a vaccine made to match a single dominant variant versus one that targets two variants? Explain briefly.

Related articles